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Background: Atrial fibrillation (AF) and coronary artery disease (CAD) are progressively prevalent as society ages. Although the incidence of 
coronary risk factors has dramatically increased and this trend is projected to continue in Japan, no data are available regarding the prevalence of 
CAD and incidence of coronary events in nonvalvular atrial fibrillation (NVAF) patients in Japan.
methods: The data in the present study was derived from Shinken Database 2004-2010, which includes 15,227 new visiting patients to the 
Cardiovascular Institute between June 2004 and March 2011. In the database, 1,835 patients were diagnosed as NVAF.
results: The prevalence of CAD in NVAF patients was 6.4% at initial visit and sharply increased from 1.0% in CHADS2 score 0 to 15.7% in CHADS2 
≥2 according to the increases in the CHADS2 score. During the follow-up period of 532±599 days, coronary events (myocardial infarction, unstable 
angina and stable angina) occurred in 51 patients (1.9%/year): 11 (1.1%/year) in CHADS2 0, 12 (1.4%/year) in CHADS2 1, and 28 (3.6%/year) in 
CHADS2 ≥2. There was a significant linear trend among CHADS2 score in percentage and annual coronary events. 
conclusion: We clarified the prevalence of CAD and incidence of coronary events in NVAF patients in Japan. This information would be served as 
the basis for decision making in daily practice regarding the intensity of the risk management and the selection of medications for antithrombosis.
